- Home
- CTMX vs NTRB Comparison
CTMX vs NTRB Comparison
Compare CTMX & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTMX
- NTRB
- Stock Information
- Founded
- CTMX 2008
- NTRB 2016
- Country
- CTMX United States
- NTRB United States
- Employees
- CTMX N/A
- NTRB N/A
- Industry
- CTMX Biotechnology: Pharmaceutical Preparations
- NTRB Industrial Specialties
- Sector
- CTMX Health Care
- NTRB Health Care
- Exchange
- CTMX Nasdaq
- NTRB Nasdaq
- Market Cap
- CTMX 60.7M
- NTRB 59.1M
- IPO Year
- CTMX 2015
- NTRB N/A
- Fundamental
- Price
- CTMX $1.99
- NTRB $5.66
- Analyst Decision
- CTMX Buy
- NTRB Buy
- Analyst Count
- CTMX 2
- NTRB 1
- Target Price
- CTMX $2.50
- NTRB $13.00
- AVG Volume (30 Days)
- CTMX 9.5M
- NTRB 56.4K
- Earning Date
- CTMX 05-12-2025
- NTRB 05-30-2025
- Dividend Yield
- CTMX N/A
- NTRB N/A
- EPS Growth
- CTMX 128.27
- NTRB N/A
- EPS
- CTMX 0.49
- NTRB N/A
- Revenue
- CTMX $147,557,000.00
- NTRB $2,139,537.00
- Revenue This Year
- CTMX N/A
- NTRB $571.50
- Revenue Next Year
- CTMX N/A
- NTRB $577.37
- P/E Ratio
- CTMX $4.90
- NTRB N/A
- Revenue Growth
- CTMX 23.81
- NTRB 2.60
- 52 Week Low
- CTMX $0.40
- NTRB $3.35
- 52 Week High
- CTMX $2.81
- NTRB $11.78
- Technical
- Relative Strength Index (RSI)
- CTMX 80.26
- NTRB 46.98
- Support Level
- CTMX $0.91
- NTRB $5.62
- Resistance Level
- CTMX $2.55
- NTRB $6.00
- Average True Range (ATR)
- CTMX 0.22
- NTRB 0.55
- MACD
- CTMX 0.18
- NTRB -0.01
- Stochastic Oscillator
- CTMX 87.53
- NTRB 10.71
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.